source
- Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effectsBoehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study. The trial reported that 19% of participants discontinued the treatm…
- Boehringer’s obesity drug cuts liver fat but lags behind competitors in weight lossData from a Phase 3 trial of Boehringer Ingelheim’s weekly injectable survodutide were presented at the American Diabetes Association meeting. Patients receiving the highest dose lost about 13% of…